WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, today announced that Elizabeth Radcliffe has joined as the company’s Vice President of Finance and Strategy. She is a business leader with deep experience in managing finance and planning across the full range of biopharmaceutical R&D and business operations, including recent roles at Agios Pharmaceuticals and Biogen. Ms. Radcliffe joins Arrakis at a pivotal time for the company as it approaches its next stage of growth to build a pipeline of novel RNA‑targeted small molecules.
“We are delighted to welcome Liz to our leadership team, as she brings a wealth of financial and strategic planning expertise that will be immensely valuable to Arrakis as we take on the enormous opportunity ahead of us,” said Michael Gilman, Ph.D., Chief Executive Officer of Arrakis. “Liz’s strategic skills, financial judgement, and breadth of knowledge across drug development and commercialization will guide our decision-making as Arrakis continues to pioneer the development of a new class of powerful RNA-targeted small-molecule medicines for patients.”
“This is an exciting time to join Arrakis as the company builds its emerging pipeline of rSM medicines, and I am eager to leverage my experience to help the company achieve its aspirations as a drug innovator,” said Ms. Radcliffe. “It is invigorating to be part of a team that is pioneering a new approach to targeting RNA to create a host of new medicines for patients across many disease areas.”
Ms. Radcliffe most recently served as Vice President, Financial Planning & Analysis, at Agios Pharmaceuticals, where she led all aspects of financial planning for this growing, fully integrated biotech company. At Agios, she spearheaded activities to transform the company’s financial management infrastructure and processes, launch Agios’s first wholly-owned commercial product, and improve strategic and long-range planning. Previously, Ms. Radcliffe had a decade-long career at Biogen, culminating in the role of Senior Director, Head of R&D Finance, leading financial planning and accounting for Biogen’s worldwide R&D and Medical Affairs budget. Prior leadership roles at Biogen included head of US revenue planning for Biogen’s Multiple Sclerosis and Hemophilia franchises, Head of Portfolio Management, and Director of Corporate FP&A, with earlier experience supporting Business Development and Technical Operations.
Earlier in her career, Ms. Radcliffe held consulting positions at The Parthenon Group and Excelon Corporation. She holds a BS in chemistry from Yale University, a Master’s degree in organic chemistry from Harvard University, and an MBA from the MIT Sloan School of Management.
About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. Arrakis is building a proprietary pipeline of RNA-targeted small molecules (rSMs) focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.
